Successful transaction: Adragos Pharma has officially taken over Clinigen’s development unit, Lamda Laboratories near Athens, Greece
Adragos on a growth path: Three locations in Europe and five globally Acquisition strengthens Adragos’ end-to-end integrated pharmaceutical product development service offering Agreement on further product development activities for Clinigen Munich / London / Athens, April 3, 2023 – Munich-based pharmaceutical contract development organization (CDMO) Adragos Pharma GmbH successfully completed the acquisition of Lamda Laboratories […]
Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories in Greece, Athens
Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment Agreement includes further product development activities for Clinigen Limited Lamda spurs further growth for Adragos as its 3rd site in Europe, and 5th globall Munich / London / Athens, March 20, 2023 – Munich-based […]
Successful transaction: Adragos Pharma has officially taken over the Sanofi production site in Kawagoe, Japan
Successful transaction: Adragos Pharma has officially taken over the Sanofi production site in Kawagoe, Japan Munich / Paris / Tokyo, March 02, 2023 – Munich-based pharmaceutical contract manufacturer (CDMO) Adragos Pharma GmbH successfully completed the acquisition of one of Japan’s leading pharmaceutical manufacturing facilities from Sanofi K.K. The transaction makes Adragos Pharma the third largest […]
Adragos Pharma to acquire Sanofi’s manufacturing site in Kawagoe, Japan
Adragos Pharma to acquire Sanofi’s manufacturing site in Kawagoe, Japan Munich / Paris / Tokyo, October 13, 2022 – Adragos Pharma, a rapidly growing pharmaceutical Contract Development and Manufacturing Organization (CDMO) based in Munich, Germany, signed definitive agreements with Sanofi K.K. for the acquisition of a pharmaceutical manufacturing site in Kawagoe, close to Tokyo, Japan. […]
FSN Capital VI partners with Prange Group to accelerate growth of Adragos Pharma
Munich / Plettenberg, 09. August 2021 – FSN Capital VI* (“FSNC”) has acquired a majority share in Adragos Pharma Group (“Adragos”), a growing B2B contract developer and manufacturer (CDMO) for pharmaceuticals. The current owner, Prange Group (“PG”), remains invested to support Adragos’ journey towards a leading global position in the highly attractive and well-protected pharmaceutical […]
